Screening of subjects has begun at clinical study sites
The Phase 2a study is being led by Principal Investigator, Dr. Stephen Harrison
Aligos anticipates dosing the first subject in Q2 2024 with topline safety and efficacy data expected in Q4 2024
March 18, 2024 -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, today announced the initiation of th